BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26959121)

  • 1. Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer.
    Guo H; Zhong Y; Jackson AL; Clark LH; Kilgore J; Zhang L; Han J; Sheng X; Gilliam TP; Gehrig PA; Zhou C; Bae-Jump VL
    Oncotarget; 2016 Apr; 7(15):20338-56. PubMed ID: 26959121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1α and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.
    Kim BR; Yoon K; Byun HJ; Seo SH; Lee SH; Rho SB
    Oncotarget; 2014 Aug; 5(15):6540-51. PubMed ID: 25153728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
    Hirasawa T; Miyazawa M; Yasuda M; Shida M; Ikeda M; Kajiwara H; Matsui N; Fujita M; Muramatsu T; Mikami M
    Int J Gynecol Cancer; 2013 Sep; 23(7):1210-8. PubMed ID: 23899586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.
    Sankpal UT; Ingersoll SB; Ahmad S; Holloway RW; Bhat VB; Simecka JW; Daniel L; Kariali E; Vishwanatha JK; Basha R
    Tumour Biol; 2016 Oct; 37(10):14259-14269. PubMed ID: 27581819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.
    Mabuchi S; Altomare DA; Connolly DC; Klein-Szanto A; Litwin S; Hoelzle MK; Hensley HH; Hamilton TC; Testa JR
    Cancer Res; 2007 Mar; 67(6):2408-13. PubMed ID: 17363557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway.
    Zhang S; Leng T; Zhang Q; Zhao Q; Nie X; Yang L
    Biomed Pharmacother; 2018 Jun; 102():302-308. PubMed ID: 29571014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway.
    Zhang N; Qiu J; Zheng T; Zhang X; Hua K; Zhang Y
    Oncol Rep; 2018 Mar; 39(3):1034-1042. PubMed ID: 29286125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer.
    Stine JE; Guo H; Sheng X; Han X; Schointuch MN; Gilliam TP; Gehrig PA; Zhou C; Bae-Jump VL
    Oncotarget; 2016 Jan; 7(1):946-60. PubMed ID: 26503475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway.
    Zhang Z; Zhu Y; Lai Y; Wu X; Feng Z; Yu Y; Bast RC; Wan X; Xi X; Feng Y
    Int J Oncol; 2013 Oct; 43(4):1194-204. PubMed ID: 23921511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
    Chen S; Zhao Y; Gou WF; Zhao S; Takano Y; Zheng HC
    PLoS One; 2013; 8(11):e79781. PubMed ID: 24236158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
    Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
    J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines.
    Drenzek JG; Seiler NL; Jaskula-Sztul R; Rausch MM; Rose SL
    Gynecol Oncol; 2011 Aug; 122(2):396-401. PubMed ID: 21616523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
    Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
    Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway.
    Chen S; Chen X; Xiu YL; Sun KX; Zhao Y
    PLoS One; 2015; 10(5):e0125714. PubMed ID: 25933027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydroartiminisin inhibits the growth and metastasis of epithelial ovarian cancer.
    Wu B; Hu K; Li S; Zhu J; Gu L; Shen H; Hambly BD; Bao S; Di W
    Oncol Rep; 2012 Jan; 27(1):101-8. PubMed ID: 22025319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention.
    Zheng N; Chen J; Li T; Liu W; Liu J; Chen H; Wang J; Jia L
    Mol Carcinog; 2017 Aug; 56(8):1896-1908. PubMed ID: 28277622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy.
    Zhao Y; Zheng HC; Chen S; Gou WF; Xiao LJ; Niu ZF
    Gynecol Oncol; 2013 Sep; 130(3):570-8. PubMed ID: 23764197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells.
    Decollogne S; Joshi S; Chung SA; Luk PP; Yeo RX; Nixdorf S; Fedier A; Heinzelmann-Schwarz V; Hogg PJ; Dilda PJ
    Gynecol Oncol; 2015 Aug; 138(2):363-71. PubMed ID: 26080289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis.
    Wei X; Liu Y; Gong C; Ji T; Zhou X; Zhang T; Wan D; Xu S; Jin P; Yang X; Li X; Ma D; Yang Z; Gao Q
    Anticancer Agents Med Chem; 2017; 17(8):1093-1101. PubMed ID: 28002999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer.
    Suri A; Sheng X; Schuler KM; Zhong Y; Han X; Jones HM; Gehrig PA; Zhou C; Bae-Jump VL
    Oncotarget; 2016 Jun; 7(26):39582-39594. PubMed ID: 27074576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.